Luzitin, S.A. is a pharmaceutical company focused on the pursuit of innovative solutions for photodynamic therapy (PDT).

Our mission is to investigate and develop innovative photosensitizing compounds to be used in Photodynamic Therapy (PDT) or Photodynamic Diagnosis (PDD) of cancer.

Latest Publications

Clinical photodynamic therapy: The evolution of photodynamic therapy treatment of head and neck cancer

Merrill A. Biel
Journal of Porphyrins and Phthalocyanines, 2024; 28: 338–348

Overcoming the challenges of infrared photosensitizers in photodynamic therapy: the making of redaporfin

Luis G. Arnaut and Mariette M. Pereira
The Royal Society of Chemistry, Issue 62, 2023

Unraveling the Pivotal Role of Atropisomerism for Cellular Internalization

Claire Donohoe, Fábio A. Schaberle, Fábio M. S. Rodrigues, Nuno P. F. Gonçalves, Christopher J. Kingsbury, Mariette M. Pereira, Mathias O. Senge, Lígia C. Gomes-da-Silva and Luis G. Arnaut
Journal of the American Chemical Society, 2022, 144, 33, 15252–15265

Bluepharma
Universidade de Coimbra
Portugal Ventures
Compete2020
Portugal2020
União Europeia